Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action
04. Dezember 2024 09:20 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Pankaj Mohan, CEO of Sonnet discusses what this publication means in a Virtual Investor “What This Means” segment; access here PRINCETON, NJ, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet...
ITI-1000 (pp65 DC vaccine) for Glioblastoma Multiforme (GBM): Emerging Drug Insights and Market Forecasts, 2019-2023 and 2023-2032 - Focus on US, Germany, France, Italy, Spain, UK, and Japan
24. Januar 2024 09:09 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "ITI-1000 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
The Fc fusion therapeutics market is anticipated to grow at an annualized rate of over 10%, claims Roots Analysis
24. März 2022 13:19 ET
|
Roots Analysis
London, March 24, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Fc Fusion Therapeutics Market, 2021-2030” report to its list of offerings. With 13 drugs approved in the...
The immunocytokines market is estimated to be worth around USD 5.4 billion by 2030, claims Roots Analysis
30. Juni 2021 10:55 ET
|
Roots Analysis
London, June 30, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of the “Immunocytokines Market, 2021-2030” report to its list of offerings. These engineered...